Loading InvisibleSignal...

Comorbidity Network

Mapping how invisible illnesses co-occur and interact. Comorbidity patterns reveal shared biological mechanisms, inform differential diagnosis, and highlight the need for coordinated, multi-system care.

Comorbidity Matrix

Overlap percentages between conditions. Darker cells indicate stronger co-occurrence.

	ME/CFS	Fibromyalgia	POTS	Lyme	Long COVID	Alpha-gal
ME/CFS	--	70%	55%	30%	40%	15%
Fibromyalgia	70%	--	45%	20%	30%	10%
POTS	55%	45%	--	18%	35%	22%
Lyme	30%	20%	18%	--	25%	12%
Long COVID	40%	30%	35%	25%	--	8%
Alpha-gal	15%	10%	22%	12%	8%	--

Key Clusters

The Triad

35% prevalence

ME/CFSFibromyalgiaPOTS

The most commonly observed overlap cluster. Patients with one of these conditions have significantly elevated odds of developing the other two, driven by shared autonomic and central sensitization pathways.

Post-Infectious

28% prevalence

LymeLong COVIDME/CFS

Infection-triggered conditions that share post-infectious immune activation, persistent microglial priming, and exercise intolerance. Research suggests a common post-infectious mechanism.

Autonomic Dysfunction

18% prevalence

POTSME/CFSAlpha-gal

Conditions linked by autonomic nervous system involvement, including orthostatic intolerance, inappropriate tachycardia, and mast cell-mediated vasodilation.

Shared Biological Mechanisms

Number of conditions sharing each common biological pathway.

Clinical Implications

Diagnostic Difficulty

Overlapping symptoms across conditions create a diagnostic maze. Fatigue, brain fog, and pain are shared by nearly all invisible illnesses, leading to an average 4.5-year delay from symptom onset to full diagnosis.

Treatment Interactions

Medications that alleviate one condition may exacerbate another. Beta-blockers for POTS can worsen ME/CFS fatigue; immunosuppressants for autoimmunity may reactivate latent infections.

Specialist Coordination

Patients often see 5+ specialists who may not communicate. A unified care model with a coordinating physician is critical to avoid contradictory treatment plans and repeated testing.

Research Implications

Clinical trials that exclude comorbid patients produce results that don't generalize to the real patient population. Inclusive trial design and shared biomarker research are urgently needed.

Patient Journey Timeline

Typical progression from initial symptoms to multiple diagnoses (average 4.5 years).

Year 0

Initial Symptoms

Fatigue, pain, or autonomic symptoms first appear

Year 0.5

Primary Care Visit

Standard labs return normal; told it's stress or anxiety

Year 1.5

First Specialist

Referred to rheumatologist or neurologist; partial workup

Year 2.5

First Diagnosis

One condition identified (often fibromyalgia or POTS)

Year 3.5

Symptom Expansion

New symptoms emerge or existing ones worsen; additional referrals

Year 4.5

Comorbid Diagnoses

Second and third conditions finally identified (avg 4.5 years)

Explore Related Modules

Compare Conditions

Side-by-side condition analysis

Pattern Engine

Cross-condition analysis

Demographics

Prevalence disparities

Treatment Guide

Evidence-based treatment info

Data Sources (3)

JGIM. Journal of General Internal Medicine. 2023.
NIH. NIH Comorbidity Studies. 2024.
Elsevier. Autoimmunity Reviews. 2024.